Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis

被引:0
作者
Chong Wang
Li-Liang Wei
Li-Ying Shi
Zhi-Fen Pan
Xiao-Mei Yu
Tian-Yu Li
Chang-Ming Liu
Ze-Peng Ping
Ting-Ting Jiang
Zhong-Liang Chen
Lian-Gen Mao
Zhong-Jie Li
Ji-Cheng Li
机构
[1] Institute of Cell Biology,Department of Respiratory Medicine
[2] Zhejiang University,Department of Clinical Laboratory
[3] The Sixth Hospital of Shaoxing,Department of Tuberculosis
[4] Zhejiang Hospital,undefined
[5] The First Hospital of Jiaxing,undefined
来源
Scientific Reports | / 5卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Rapid and efficient methods for the determination of cured tuberculosis (TB) are lacking. A total of 85 differentially expressed serum proteins were identified by iTRAQ labeling coupled with two-dimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) analysis (fold change >1.50 or <0.60, P < 0.05). We validated albumin (ALB), Rho GDP-dissociation inhibitor 2 (ARHGDIB), complement 3 (C3), ficolin-2 (FCN2) and apolipoprotein (a) (LPA) using the enzyme-linked immunosorbent assay (ELISA) method. Significantly increased ALB and LPA levels (P = 0.036 and P = 0.012, respectively) and significantly reduced ARHGDIB, C3 and FCN2 levels (P < 0.001, P = 0.035 and P = 0.018, respectively) were observed in cured TB patients compared with untreated TB patients. In addition, changes in ALB and FCN2 levels occurred after 2 months of treatment (P < 0.001 and P = 0.030, respectively). We established a cured TB model with 87.10% sensitivity, 79.49% specificity and an area under the curve (AUC) of 0.876. The results indicated that ALB, ARHGDIB, C3, FCN2 and LPA levels might serve as potential biomarkers for cured TB. Our study provides experimental data for establishing objective indicators of cured TB and also proposes potential markers for evaluating the efficacy of anti-TB drugs.
引用
收藏
相关论文
共 76 条
  • [1] Kargar M(2014)Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature Expert Opin Drug Saf 13 875-891
  • [2] Wilkinson D(1998)Should we take a history of prior treatment and check sputum status at 2–3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis 2 52-55
  • [3] Bechan S(2015)Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies Lancet Respir Med 3 201-209
  • [4] Connolly C(2013)An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse PLoS One 8 e63840-372
  • [5] Standing E(2013)Tuberculosis biomarkers discovery: developments, needs and challenges Lancet Infect Dis 13 362-196
  • [6] Short GM(2014)Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis Tuberculosis (Edinb) 94 187-184
  • [7] Kurbatova EV(2014)Association of serum levels of iron, copper and zinc and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment Biol Trace Elem Res 160 176-8
  • [8] Phillips PP(2005)IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection Microbes Infect 7 1-331
  • [9] Fielding K(2013)Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment PLoS One 8 e61002-91
  • [10] Nunn AJ(2014)Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS Proteomics 14 322-177